Target intelligence / Profile preview

Cardiac sodium channel protein type 5 subunit alpha (NaV1.5) (NaV1.5)

Target
NaV1.5
Molecular classification
Ion channel, Voltage-gated sodium channel
01

Overview

The cardiac sodium channel protein type 5 subunit alpha (NaV1.5), encoded by the SCN5A gene, forms the primary ion channel responsible for the rapid upstroke (phase 0) of the cardiac action potential, enabling rapid electrical conduction across the heart muscle[3][5]. In addition to the large, transient early sodium current, a small fraction of these channels either fail to inactivate or reopen during the plateau phase, generating a sustained or "late" sodium current (I_Na,late)[1][2][3]. This late current, although much smaller in magnitude, significantly influences action potential duration and intracellular sodium and calcium levels, with overactivity implicated in various cardiac pathologies such as arrhythmias and heart failure[2][3]. Drugs targeting this late current are used as antiarrhythmic agents and are under investigation for other cardiac indications[2][3].

Other names
Cardiac sodium channelVoltage-gated sodium channel subunit alpha Nav1.5SCN5A (gene)Late sodium current (I_Na,late)
02

Mechanism of action

Inhibition of the late sodium current to reduce prolonged action potential duration and decrease intracellular sodium and calcium overload Blockade of voltage-gated sodium channels to suppress abnormal electrical activity

03

Biological functions

Initiation and propagation of cardiac action potentialsRegulation of cardiac excitability and conductionContribution to the action potential plateau (via late sodium current)Modulation of intracellular sodium and calcium homeostasis
04

Disease associations

Cardiovascular diseaseArrhythmias (e.g., long QT syndrome type 3, Brugada syndrome)Heart failureMyocardial ischemiaAngina
05

Safety considerations

Proarrhythmia (induction of torsades de pointes or other dangerous arrhythmias)Negative inotropic effects (weakening of heart contraction)Risk of conduction abnormalities and heart block
06

Interacting drugs

Ranolazine

6 more in the full profile.

07

Biomarkers

SCN5A gene mutations (particularly for arrhythmic syndromes)Prolonged QT interval (for monitoring efficacy or risk)

Beyond the preview

Go deeper on Cardiac sodium channel protein type 5 subunit alpha (NaV1.5) (NaV1.5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cardiac sodium channel protein type 5 subunit alpha (NaV1.5) (NaV1.5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call